(Q44016865)

29 November 2017

Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells (English)

1 reference

29 November 2017

Milka C Georgieva

1

1 reference

29 November 2017

Spiro M Konstantinov

series ordinal

2

1 reference

29 November 2017

Margarita Topashka-Ancheva

series ordinal

3

1 reference

29 November 2017

Martin R Berger

series ordinal

4

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

29 November 2017

1 reference

29 November 2017

182

1 reference

29 November 2017

2

1 reference

29 November 2017

163-174

1 reference

Alkylphosphocholines: a new class of membrane-active anticancer agents

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

The influence of 1-beta-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Mechanisms of synergism between gemcitabine and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2802%2900088-5

7 January 2021

10.1016/S0304-3835(02)00088-5

Identifiers

DOI

1 reference

29 November 2017

1 reference